Results 271 to 280 of about 1,009,444 (403)

Molecular Frameworks for ERK1/2 Inhibition: Lessons from Synthetic and SAR Explorations. [PDF]

ACS Omega
Muthukumar V, Vashishth A, Maniam S, Ghosh B.   +3 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Improved reconstruction of single-cell developmental potential with CytoTRACE 2. [PDF]

Nat Methods
Kang M, Gulati GS, Brown EL, Qi Z, Avagyan S, Armenteros JJA, Gleyzer R, Zhang W, Steen CB, D'Silva JP, Schwab J, Clarke MF, Chaudhuri AA, Newman AM.   +13 more
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Uncovering molecular determinants of potency and binding affinity in hit compounds targeting FGF14/Nav1.6 complex. [PDF]

J Cheminform
Teimouri H, Haghighijoo Z, Baumgartner TJ, Singh AK, Wadsworth PA, Zhang C, Chen H, Zhou J, Laezza F.   +8 more
europepmc   +1 more source

Nanoparticles, Potency Selection, and Cellular Targeting in Homeopathic Medicine: A Scientific Bridge Between Hahnemann's Principles and Modern Nanomedicine [PDF]

Ankur Mishra
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Reply to Peigneur et al. The Helix Ring Peptide U11 from the Venom of the Ant, <i>Tetramorium bicarinatum</i>, Acts as a Putative Pore-Forming Toxin, Not a New Kv1.3 Channel Blocker. Comment on "Boy et al. A New Kv1.3 Channel Blocker from the Venom of the Ant <i>Tetramorium bicarinatum</i>. <i>Toxins</i> 2025, <i>17</i>, 379". [PDF]

Toxins (Basel)
Boy G, Jouvensal L, Téné N, Carayon JL, Bonnafé E, Paquet F, Treilhou M, Loth K, Billet A.   +8 more
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source